Now that there are several targeted biotech drugs on the market, researchers are starting to test whether two targeted drugs are better than one. 既然市场上有很多靶向生物技术药物,那么研究者正开始试验两个靶向药物是否会比一个更好些。
Preliminary research suggests that mitochondria-rejuvenating drugs are capable, at least in lab animals, of halting these diseases and extending longevity. 初步研究表明,线粒体靶向药物是有效的,至少在动物实验中证明它可以制止这些疾病并延长寿命。